α-Emitting cancer therapy using <sup>211</sup> At-AAMT targeting LAT1.

导出 OA

翻译打印收藏纠错

作者： Kazuko,Kaneda-Nakashima ^[1] ; ZiJian,Zhang ^[2] ; Yoshiyuki,Manabe ^[2] ; Atsushi,Shimoyama ^[3] ; Kazuya,Kabayama ^[1] ; Tadashi,Watabe ^[2] ; Yoshikatsu,Kanai ^[3] ; Kazuhiro,Ooe ^[1] ; Atsushi,Toyoshima ^[2] ; Yoshifumi,Shirakami ^[3] ; Takashi,Yoshimura ^[1] ; Mitsuhiro,Fukuda ^[2] ; Jun,Hatazawa ^[3] ; Takashi,Nakano ^[1] ; Koichi,Fukase ^[4] ; Atsushi,Shinohara ^[1]

作者单位： Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan. ^[1] MS-CORE, PRC, Graduate School of Science, Osaka University, Osaka, Japan. ^[2] Laboratory for Natural Product Chemistry, Department of Chemistry, Graduate School of Science, Osaka University, Osaka, Japan. ^[3] Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, Osaka, Japan. ^[4] Department of Bio-System Pharmacology, Graduate School of Medicine, Osaka University, Osaka, Japan. ^[5] Radioisotope Research Center, Institute for Radiation Sciences, Osaka University, Osaka, Japan. ^[6] Research Center for Nuclear Physics, Osaka University, Osaka, Japan. ^[7] Laboratory for Radiochemistry, Department of Chemistry, Graduate School of Science, Osaka University, Osaka, Japan. ^[8]

关键词 amino acid anti-cancer drug astatine-211 large neutral amino acid transporter 1 nuclear medicine